Taken together, the F3.CD-TK treatment more efficaciously killed G55 cells, which, acting alongside its effects on tumor topology modification, neuroinflammation/neuroimmune modulation, and neural repair, jointly stalled C6-ISCG growth and resultant neurological deficits. This evidence concerns the gene TKT and neoplasm.